Chiara Parsons
Breast cancer is becoming more common across the world, with over 600,000 deaths recorded in 2018. Surgery, chemotherapy, radiotherapy, or targeting of classical breast cancer subtype markers such as estrogen receptor (ER) and HER2 are currently available treatment choices for breast cancer patients. These medications, however, are ineffective in preventing recurrence and metastasis. Improved knowledge of breast cancer and metastasis biology will aid in the discovery of new biomarkers and therapeutic opportunities to help patients be better stratified and treated.
